Radius Health Inc. diskutieren
Radius Health Inc.
WKN: A114VH / Symbol: RDUS / Name: Radius Health / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
9,82 €
-
(Laufzeit überschritten)
(Laufzeit überschritten)
Radius Health could Advance 50% With Osteoporosis Treatment
Morgan Stanley analyst initiated coverage of the company with an Overweight rating and a $57 price target.
Radius is set to launch Tymlos, a bone builder for women with osteoporosis, but despite Eli Lilly's presence in the market with Forteo, which fetched the company $1 billion in sales and is exposed to generic competition in 2019, the analyst said Tymlos' pricing is 40 percent lower than Forteo's — and
convenience could help it grab share.
Radius Health is a Conviction Buy!
SecteurRecherche biotechnologique et médicale Agenda 13/09 | 19:30 Présentation
Develops drug therapies for the treatment of osteoporosis and other women's health conditions
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology.
The firm's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.
Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women.
The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology.
The firm's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.
Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women.
The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
Nombre d'employés : 561 personnes.
(Vom Mitglied beendet)
Kursziel geändert auf 41,414
Sell mit Kursziel 13,0
Buy mit Kursziel 16,0
Buy mit Kursziel 11,0
Kursziel geändert auf 21,414
Sell Radius Health Inc.
Buy mit Kursziel 15,0
Buy Radius Health Inc.
Sell Radius Health Inc.
Buy mit Kursziel 13,0
Buy Radius Health Inc.
Buy mit Kursziel 13,0
Buy Radius Health Inc.
Sell Radius Health Inc.
Sell Radius Health Inc.
Neueste Beiträge
MBU in Varta AG diskutieren